Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension
Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension: a Multicenter Observational Study
Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors. However, cirrhosis might be associated with upper gastrointestinal bleeding, particularly in case of portal hypertension or coagulopathy. This study aims to assess safety, efficacy and methods to prevent potential complications in cirrhosis or portal hypertension context for esophageal endoscopic resection.
This retrospective multicentric French-Belgian study includes all consecutive patients with cirrhosis or portal hypertension who underwent esophageal endoscopic resection from January 2005 to 2021.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Study Population
Description
Inclusion Criteria:
- older than 18 years with cirrhosis or portal hypertension who underwent endoscopic resection of an early esophageal tumor
Exclusion Criteria:
- younger than 18
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cirrhotic patients or with portal hypertension
Patients with early esophageal cancer
|
under general anesthesia, by mucosectomy or endoscopic submucosal dissection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
technical success of early esophageal cancer resection
Time Frame: baseline
|
defined by a complete macroscopic resection
|
baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
adverse events per procedure (immediate bleeding, perforation)
Time Frame: baseline
|
baseline
|
|
morbidity post procedure (delayed bleeding, infection, esophageal stenosis, 30-days related liver decompensation, 30-days related mortality)
Time Frame: up to 4 weeks
|
up to 4 weeks
|
|
Potential risk factors for adverse events
Time Frame: baseline
|
baseline
|
|
preemptive methods to the risk of bleeding
Time Frame: baseline
|
baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Liver Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Fibrosis
- Hypertension
- Liver Cirrhosis
- Esophageal Neoplasms
- Hypertension, Portal
Other Study ID Numbers
Other Study ID Numbers
- 2019PI67
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Neoplasms
-
NCT02392377TerminatedStage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal Adenocarcinoma
-
NCT07416825CompletedEsophageal Cancer | Esophageal Carcinoma
-
NCT06745193Not yet recruiting
-
NCT07309991RecruitingEsophageal Adenocarcinoma | Esophageal Carcinoma | Esophagectomy | PaO2 | Esophageal Anastomotic Leakeage
-
NCT00570531TerminatedLoco-regional Esophageal Cancer
-
NCT01927016CompletedEsophageal Neoplasm | Esophageal Disease
-
NCT01269970CompletedEsophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)
-
NCT03708042Not yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
NCT02959385UnknownStage III Esophageal Cancer | Stage II Esophageal Cancer
-
NCT01490749CompletedEsophageal Cancer | Neoplasms, Esophageal
Clinical Trials on Endosocpic resection of early esophageal tumor
-
NCT07642102CompletedBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Transurethral Resection of Bladder Tumor
-
NCT06119724Active, not recruiting
-
NCT04029948UnknownUrinary Bladder Neoplasm
-
NCT07534631Completed
-
NCT07347132CompletedUrinary Bladder Neoplasms | Non-muscle Invasive Bladder Cancer
-
NCT06820502Active, not recruitingBladder Cancer | BPH (Benign Prostatic Hyperplasia) | Bladder Cancer Recurrence
-
NCT02149784UnknownColorectal Cancer Metastatic
-
NCT06118723RecruitingGlioblastoma | Brain Neoplasms | Astrocytoma, Grade III | High-grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Brain Neoplasm, Primary | Brain Neoplasm, Malignant